Your browser is no longer supported. Please, upgrade your browser.
Settings
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E731.13 EPS (ttm)0.13 Insider Own1.00% Shs Outstand91.39M Perf Week2.49%
Market Cap8.89B Forward P/E27.61 EPS next Y3.52 Insider Trans-31.37% Shs Float90.38M Perf Month12.81%
Income18.10M PEG- EPS next Q0.63 Inst Own- Short Float4.49% Perf Quarter23.48%
Sales605.20M P/S14.68 EPS this Y113.70% Inst Trans2.23% Short Ratio6.10 Perf Half Y23.23%
Book/sh5.29 P/B18.38 EPS next Y303.90% ROA1.80% Target Price111.33 Perf Year-15.02%
Cash/sh6.78 P/C14.33 EPS next 5Y- ROE4.00% 52W Range64.72 - 126.98 Perf YTD36.17%
Dividend- P/FCF201.06 EPS past 5Y18.30% ROI4.20% 52W High-23.41% Beta1.26
Dividend %- Quick Ratio7.30 Sales past 5Y174.10% Gross Margin99.00% 52W Low50.28% ATR2.85
Employees585 Current Ratio7.40 Sales Q/Q89.50% Oper. Margin1.60% RSI (14)62.08 Volatility2.26% 3.19%
OptionableYes Debt/Eq0.00 EPS Q/Q925.30% Profit Margin3.00% Rel Volume0.80 Prev Close97.24
ShortableYes LT Debt/Eq0.82 EarningsJul 29 AMC Payout0.00% Avg Volume666.14K Price97.26
Recom1.80 SMA202.40% SMA509.09% SMA20014.61% Volume516,715 Change0.02%
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Aug-20-19 03:54PM  Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
08:33AM  Should You Be Worried About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) 3.7% Return On Equity? Simply Wall St.
01:03AM  Another 1% Rally Provides a Strong Start to the Week Zacks
Aug-14-19 09:53AM  Why Neurocrine (NBIX) Could Be Positioned for a Surge Zacks
Aug-13-19 09:36AM  Moving Average Crossover Alert: Neurocrine Biosciences Zacks
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-09-19 09:25AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:16PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares GuruFocus.com
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 08:30AM  AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women PR Newswire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
10:20AM  Why Neurocrine (NBIX) Might be Well Poised for a Surge Zacks
Jul-30-19 12:25PM  Why Neurocrine Biosciences Stock Is Jumping Today Motley Fool +10.33%
07:50AM  Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom Investor's Business Daily
06:00AM  Neurocrine Biosciences Posts Sizzling Sales Growth in Q2 Motley Fool
05:23AM  Neurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript Motley Fool
Jul-29-19 05:25PM  Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Second Quarter 2019 Financial Results PR Newswire
Jul-26-19 08:31AM  Should You Buy Neurocrine (NBIX) Ahead of Earnings? Zacks
Jul-22-19 07:28PM  8 Health-Care Stocks for Your Portfolio Kiplinger
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-15-19 10:17AM  Does Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Reflect Performance? Simply Wall St.
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
Jul-10-19 04:10PM  Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease PR Newswire
Jul-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results PR Newswire
Jun-11-19 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders PR Newswire
01:49PM  Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Jun-04-19 04:01PM  Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
03:12AM  Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
May-31-19 11:51AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount? Simply Wall St.
May-30-19 04:01PM  Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference PR Newswire +5.99%
May-29-19 09:15AM  Not Ready to Rally Zacks
May-21-19 08:00AM  AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
May-20-19 08:00AM  Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life PR Newswire
May-16-19 04:01PM  Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting PR Newswire
May-08-19 09:15AM  Trade Anxieties Return with a Vengeance Zacks
May-07-19 04:01PM  Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
May-06-19 08:00AM  Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients PR Newswire
May-05-19 09:05AM  Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting PR Newswire
09:00AM  Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations PR Newswire
Apr-30-19 04:01PM  Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting PR Newswire -5.90%
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
Apr-29-19 10:38PM  Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript Motley Fool
04:15PM  Neurocrine: 1Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2019 Financial Results PR Newswire
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-20-19 08:24PM  Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ? Insider Monkey
Apr-16-19 11:31AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company? Simply Wall St.
Apr-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results PR Newswire
Apr-01-19 07:45AM  Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-28-19 04:15PM  Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinsons Disease in the Annals of Neurology GlobeNewswire
Mar-23-19 10:02AM  2 Biotech Takeout Targets Perfect for Biogen Motley Fool
Mar-20-19 10:43AM  Sage Stock Pops on FDA Approval for Postpartum Depression Drug InvestorPlace
Mar-15-19 09:30AM  CTLT or NBIX: Which Is the Better Value Stock Right Now? Zacks
Mar-12-19 08:00AM  Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia PR Newswire
Mar-07-19 09:15AM  Stocks Slide for Third Straight Day Zacks
Mar-05-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Mar-01-19 12:33PM  Why These 2 Biotech Stocks Might Be Next On The Takeover List Investor's Business Daily
Feb-28-19 11:56AM  Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Is An Attractive Investment To Consider Simply Wall St.
Feb-22-19 11:31AM  Voyager Therapeutics stock jumps on 2nd Parkinson's deal American City Business Journals
Feb-21-19 06:01PM  Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-12-19 09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Feb-08-19 06:48AM  Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-06-19 08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 08:04PM  Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:35PM  Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates Zacks
05:37PM  Neurocrine: 4Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results PR Newswire
02:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
Jan-31-19 02:45PM  Here are Boston-area biotechs pursuing Parkinson's treatments American City Business Journals
Jan-29-19 01:42PM  Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today Motley Fool
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
07:00AM  Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinsons Disease and Friedreichs Ataxia GlobeNewswire
Jan-28-19 09:33AM  Will Neurocrine Biosciences Continue to Surge Higher? Zacks
Jan-25-19 07:45AM  Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-16-19 04:01PM  New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders PR Newswire
06:57AM  4 Defensive Stocks to Buy Amid Shutdown and Brexit Zacks
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results PR Newswire
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences ACCESSWIRE
Jan-11-19 04:25PM  Biotech Stocks Are Enjoying Their Best-Ever Start to the Year Bloomberg
01:32PM  Is Neurocrine Biosciences, Inc.s (NASDAQ:NBIX) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 12:42PM  Neurocrine Gives Ingrezza Sales View, Updates on Pipeline Zacks +9.57%
07:15AM  Neurocrine Biosciences Is a Pharma Stock to Watch InvestorPlace
06:50AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology ACCESSWIRE
Jan-06-19 06:30PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones PR Newswire
10:56AM  Neurocrine Biosciences Looks Oversold GuruFocus.com
Jan-02-19 04:01PM  Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-31-18 07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool
Dec-14-18 08:37AM  Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't? Zacks
Dec-13-18 06:55AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals ACCESSWIRE
Dec-12-18 04:35PM  Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today Motley Fool -13.91%
12:49PM  Why Neurocrine Biosciences Is Tanking Motley Fool
07:39AM  Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal MarketWatch
07:30AM  Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome PR Newswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
Bozigian Haig P.Chief Development OfficerJul 30Option Exercise38.9144,3561,725,704167,576Jul 31 07:11 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Option Exercise32.9950,0001,649,500168,408Jul 31 07:12 PM
Lippoldt DarinChief Legal OfficerJul 30Option Exercise18.1515,831287,33335,792Jul 31 07:14 PM
LYONS GARY ADirectorJul 30Sale92.0710,000920,686235,697Jul 31 07:15 PM
Lippoldt DarinChief Legal OfficerJul 30Sale92.1315,8311,458,56919,961Jul 31 07:14 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Sale92.9260,0005,575,438108,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 30Sale92.7744,3564,114,858141,976Jul 31 07:11 PM
Bozigian Haig P.Chief Development OfficerJul 15Option Exercise32.9930,6801,012,133172,656Jul 17 07:08 PM
Bozigian Haig P.Chief Development OfficerJul 15Sale87.5030,6802,684,506141,976Jul 17 07:08 PM
BENEVICH ERICChief Commercial OfficerJul 15Sale87.445,835510,20114,910Jul 17 07:06 PM
Bozigian Haig P.Chief Development OfficerJul 11Option Exercise32.991003,299142,076Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 11Sale87.591008,759141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Option Exercise32.997,120234,889149,096Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Sale87.637,120623,958141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJun 18Option Exercise32.992,10069,279144,076Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 18Sale87.822,100184,417141,976Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 13Option Exercise20.7017,268357,469157,812Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 13Sale82.6217,2681,426,628141,976Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 03Option Exercise19.593,43567,292145,411Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerJun 03Sale85.513,435293,719141,976Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerMay 31Option Exercise19.5919,297378,028161,273Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 31Sale85.0219,2971,640,581141,976Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 24Option Exercise19.5917,486342,551159,462May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 24Sale80.0317,4861,399,434141,976May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 22Option Exercise19.591,30025,467143,276May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 22Sale80.031,300104,037141,976May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 16Option Exercise17.5866,6671,171,789176,352May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 16Sale80.1366,6675,341,893141,976May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 13Option Exercise8.6634,547299,177176,523May 15 07:23 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 13Sale75.441,657125,007118,408May 15 07:24 PM
Bozigian Haig P.Chief Development OfficerMay 13Sale75.5134,5472,608,813141,976May 15 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale83.5892076,89419,238Feb 08 05:11 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale84.0353144,622120,065Feb 08 05:09 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale83.5279166,06319,646Feb 08 05:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale84.234,096344,986417,597Feb 08 05:09 PM
Gano KyleChief Business Development OffFeb 06Sale83.5676263,67385,833Feb 08 05:07 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale83.5792076,88320,745Feb 08 05:06 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale83.5492076,859141,639Feb 08 05:06 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale88.141,272112,11916,574Feb 06 06:06 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale88.091,225107,91117,482Feb 06 06:05 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale88.171,07094,338118,322Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 05Sale88.122,434214,48280,989Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale88.194,489395,895410,185Feb 06 06:03 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale88.011,357119,42717,595Feb 06 05:59 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale88.141,350118,986138,244Feb 06 05:59 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 04Sale88.121,375121,167117,066Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 04Sale88.141,375121,18680,117Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 04Sale88.103,125275,321408,082Feb 06 06:03 PM
Bozigian Haig P.Chief Development OfficerFeb 04Sale88.101,375121,139137,372Feb 06 05:59 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale84.091,857156,1593,143Jan 10 04:47 PM
ABERNETHY MATTChief Financial OfficerDec 03Sale90.001,178106,0201,947Dec 06 05:54 PM
POPS RICHARD FDirectorNov 26Sale91.374,124376,79029,512Nov 27 06:58 PM
POPS RICHARD FDirectorNov 12Sale103.304,123425,89333,636Nov 13 06:18 PM
Bozigian Haig P.Chief Development OfficerNov 08Option Exercise8.6636,295314,147155,498Nov 13 04:15 PM
Bozigian Haig P.Chief Development OfficerNov 08Sale110.0036,2953,992,450135,997Nov 13 04:15 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Option Exercise15.453,30050,98518,618Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 07Option Exercise12.6229,399371,105151,043Nov 08 05:04 PM
Bozigian Haig P.Chief Development OfficerNov 07Sale110.1429,3993,238,132135,997Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 07Sale110.003,300363,00015,318Nov 08 05:03 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Option Exercise15.455,70088,06521,018Nov 08 05:03 PM
Bozigian Haig P.Chief Development OfficerNov 06Option Exercise35.999,420339,026145,417Nov 08 05:04 PM
Bozigian Haig P.Chief Development OfficerNov 06Sale110.109,4201,037,167135,997Nov 08 05:04 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 06Sale110.025,700627,09615,318Nov 08 05:03 PM
LYONS GARY ADirectorNov 02Sale114.4115,0001,716,213245,697Nov 05 04:11 PM
POPS RICHARD FDirectorOct 29Sale107.135,500589,23737,759Oct 30 05:58 PM
Grigoriadis Dimitri E.Chief Research OfficerSep 04Option Exercise12.2132,749399,977115,691Sep 05 08:41 PM